Advances in imaging evaluate the biology of the disease and, in doing so, allow more accurate detection of the location, extent, and aggressiveness of the malignancy.12 Magnetic resonance imaging (MRI) of the prostate may be used in many clinical scenarios, including primary screening, active surveillance, and in patients with a previous negative biopsy and rising PSA level.14 Technical advances in MRI in the last decade have made this method the preferred imaging modality for prostate anatomy and PCa risk assessment. The gene discussed is KLK3; the disease is posterior cortical atrophy.